Article
Effect of CES1 and ABCB1 genotypes on the pharmacokinetics and clinical outcomes of dabigatran etexilate in patients with atrial fibrillation and chronic kidney disease.
Drug metabolism and personalized therapy - 5 Mar 2020
Sychev Dmitriy, Skripka Alena, Ryzhikova Kristina, Bochkov Pavel, Shevchenko Roman, Krupenin Pavel, Ivashchenko Dmitriy, Kogay Veronika, Listratov Alexander, Krainyaya Arina, Gurinovich Olga, Sokolova Anastasiya, Napalkov Dmitriy, Fomin Viktor
Abstract excerpt
Background Despite the well-studied safety profile of dabigatran, its interactions with genetic polymorphism parameters are poorly understood, especially in patients with moderate chronic kidney disease (CKD). The study assessed whether genetic factors can contribute to CKD and alter dabigatran concentration. Methods Patients with atrial fibrillation (AF) and stage 3 CKD treated with dabigatran 110 or 150 mg have...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.